Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker add-on study for neoadjuvant trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction adenocarcinoma
jRCT1030210361Recruiting
- Sponsor
- National Cancer Center Hospital East
- Start
- Oct 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab deruxtecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by National Cancer Center Hospital East. Primary endpoints: Cancer-related genetic abnormality biomarker analysis, Immunohistochemistry and proteomic biomarker analysis and 2 more. Started Oct 2021; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT1030210361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030210361.